Pre-transjugular-intrahepatic-portosystemic-shunt measurement of hepatic venous pressure gradient and its clinical application: A comparison study

Figure 1 Flow chart of the patients involved. HVPG: Hepatic venous pressure gradient; TIPS: Transjugular intrahepatic portosystemic shunt.

Figure 2 Images taken in hepatic venous pressure gradient measurement and transjugular intrahepatic portosystemic shunts. A: A 68-year-old male received endoscopic therapy with non-selective β-blockers, whose hepatic venous pressure gradient (HVPG) is 16mmHg; B: A 57-year-old female received covered transjugular intrahepatic portosystemic shunts, whose HVPG is 19.6 mmHg.

Figure 3 Comparison of transplant-free survival rates between the patients with endoscopic therapy+non-selective β-blockers and covered transjugular intrahepatic portosystemic shunts during the whole follow-up period. A: The total cohort; B: Patients on low-hepatic venous pressure gradient (HVPG) tier; C: Patients on high-HVPG tier; D: Patients with viral cirrhosis or alcoholic cirrhosis; E: Patients with viral cirrhosis or alcoholic cirrhosis on low-HVPG tier; F: Patients with viral cirrhosis or alcoholic cirrhosis on high-HVPG tier; TIPS: Transjugular intrahepatic portosystemic shunt; NSBBs: Non-selective β-blockers.

Figure 4 Comparison of the rebleeding-free rate between the patients with endoscopic therapy+non-selective β-blockers and covered transjugular intrahepatic portosystemic shunts. A: The total cohort; B: Patients on low-hepatic venous pressure gradient (HVPG) tier; C: Patients on high-HVPG tier; TIPS: Transjugular intrahepatic portosystemic shunt; NSBBs: Non-selective β-blockers.

Figure 5 Changes in total bilirubin after therapy at baseline, 1-year follow-up, 2-year follow-up and the endpoint of follow-up. A: Patients received endoscopy therapy + non-selective β-blockers (NSBBs); B: Patients received covered transjugular intrahepatic portosystemic shunt (TIPS); C: Patients received endoscopy therapy + NSBBs in the low-hepatic venous pressure gradient (HVPG) tier; D: Patients received covered TIPS in the low-HVPG tier; E: Patients received endoscopy therapy+NSBBs in the high-HVPG tier; F: Patients received covered TIPS in the high-HVPG tier.

Figure 6 Changes in the depths of ascites after therapy at baseline, 1-year follow-up, 2-year follow-up and the endpoint of follow-up. A: Patients received endoscopy therapy + non-selective β-blockers (NSBBs); B: Patients received covered transjugular intrahepatic portosystemic shunt (TIPS); C: Patients received endoscopy therapy + NSBBs in the low-hepatic venous pressure gradient (HVPG) tier; D: Patients received covered TIPS in the low-HVPG tier; E: Patients received endoscopy therapy + NSBBs in the high-HVPG tier; F: Patients received covered TIPS in the high-HVPG tier.

Figure 7 Changes in the model for end-stage liver disease scores after therapy at baseline, 1-year follow-up, 2-year follow-up and the endpoint of follow-up. A: Patients received endoscopy therapy + non-selective β-blockers (NSBBs); B: Patients received covered transjugular intrahepatic portosystemic shunt (TIPS); C: Patients received endoscopy therapy + NSBBs in the low-hepatic venous pressure gradient (HVPG) tier; D: Patients received covered TIPS in the low-HVPG tier; E: Patients received endoscopy therapy + NSBBs in the high-HVPG tier; F: Patients received covered TIPS in the high-HVPG tier.